Orbital outcomes after orbit-sparing surgery and free flap reconstruction.


Journal

Oral oncology
ISSN: 1879-0593
Titre abrégé: Oral Oncol
Pays: England
ID NLM: 9709118

Informations de publication

Date de publication:
11 2019
Historique:
received: 07 06 2019
revised: 07 08 2019
accepted: 22 09 2019
pubmed: 29 9 2019
medline: 22 7 2020
entrez: 29 9 2019
Statut: ppublish

Résumé

To identify functional outcome and orbital complication rate of the preserved orbit and to identify predictors of orbital impairment in periorbital free flap reconstruction. A retrospective review was conducted on patients undergoing orbit-sparing surgery with periorbital free flap reconstruction at a tertiary institution from 2006 to 2017. Orbital complication rate and orbital functional outcomes were analyzed. A univariable and multivariable logistic regression analysis was used to assess predictors of functional outcome. Forty-nine patients met inclusion criteria. Ninety-eight percent of patients maintained a functional eye post-operatively. Most periorbital free flaps, 37 (75.5%), were performed following oncologic resection. Overall orbital function was graded as functional without impairment in 29 (59.2%) patients, functional with impairment in 19 (38.8%) patients, and nonfunctional in 1 (2.0%) patient. Postoperative orbital sequelae occurred in 32 (65.3%) patients. Twenty-one (42.9%) patients underwent 35 revision operations for late orbital sequelae. Extent of resection (OR, 5.93; CI 95%, 1.05-33.4; p = 0.044) and adjuvant RT (OR, 4.69; CI 95% 1.18-18.6; p = 0.028) significantly correlated with impairment in a functional orbit on multivariable analysis. Orbit-sparing surgery with periorbital free flap reconstruction carries a significant risk of a variety of orbital sequelae, most commonly ectropion, requiring surgical intervention. However, most patients maintain a functional eye. The need for delayed exenteration/enucleation is low and is primarily limited to cancer recurrence. Significant predictors of complications include extent of resection and adjuvant radiation therapy.

Identifiants

pubmed: 31563040
pii: S1368-8375(19)30332-X
doi: 10.1016/j.oraloncology.2019.09.023
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

78-84

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Ramez Philips (R)

Department of Otolaryngology-Head & Neck Surgery, Thomas Jefferson University Hospitals, Philadelphia, PA 19107, United States. Electronic address: ramez.philips@jefferson.edu.

Michael C Topf (MC)

Department of Otolaryngology-Head & Neck Surgery, Thomas Jefferson University Hospitals, Philadelphia, PA 19107, United States.

Alexander Graf (A)

Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, United States.

Howard Krein (H)

Department of Otolaryngology-Head & Neck Surgery, Thomas Jefferson University Hospitals, Philadelphia, PA 19107, United States.

Ryan Heffelfinger (R)

Department of Otolaryngology-Head & Neck Surgery, Thomas Jefferson University Hospitals, Philadelphia, PA 19107, United States.

Adam Luginbuhl (A)

Department of Otolaryngology-Head & Neck Surgery, Thomas Jefferson University Hospitals, Philadelphia, PA 19107, United States.

Joseph Curry (J)

Department of Otolaryngology-Head & Neck Surgery, Thomas Jefferson University Hospitals, Philadelphia, PA 19107, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH